SK Hynix Shares Fall as Workers Reject Wage Deal 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Trump Buys SpaceX Shares After Record IPO 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Add as a preferred source on Google
TORONTO, May 01, 2018 -- Polydex Pharmaceuticals Limited (OTC Pink:POLXF) (the “Company”) reports financial results for its fiscal year ended January 31, 2018. All figures are reported in U.S. dollars.
| Fiscal Year End 2018 | Fiscal Year End 2017 | ||
| Sales | $5,279,040 | $6,621,330 | |
| Net Income (Loss) | 448,789 | 669,259 | |
| Income (Loss) per common share | Basic | 0.13 | 0.20 |
| Diluted | 0.13 | 0.19 | |
| Weighted avg. common shares outstanding | Basic | 3,409,728 | 3,390,228 |
| Diluted | 3,466,649 | 3,504,508 | |
Gross margins have been maintained and, combined with management efforts; a solid financial position has resulted. EBITDA remains strong at $765,742, with a working capital ratio of 3.15. Management is also hopeful that the registration of a new product could result in $250,000 of additional supply agreement fees in fiscal 2019 or 2020.
“We have made significant investments into production again this year,” said company President and CEO George Usher. “Another $375,000.00 dedicated to upgraded equipment has simultaneously resulted in increased production capability and reduced utilities costs. We are also in the fortunate position of beginning this fiscal year with $1.2 million in cash and investments on hand, and accounts receivable of a further $1.5 million. This will allow us to continue to prudently invest in more efficient equipment that will lead to either further savings or increased control the rising cost of utilities.”
The Company’s publicly traded shares continue to be quoted on the OTC Pink platform
(www.otcmarkets.com/stock/POLXF/quote).
Polydex Pharmaceuticals Limited, based in Toronto, Ontario, Canada, is engaged in the manufacture of bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry and also the development, manufacture and marketing of biotechnology-based products for the human pharmaceutical market. Company website: www.Polydex.com
Note: This press release may contain forward-looking statements, within the meaning of the United States Securities Act of 1933, as amended, and the United States Securities Exchange Act of 1934, as amended, regarding Polydex Pharmaceuticals Limited, including, without limitation, statements regarding expectations about future revenues or business opportunities or potential research projects. These statements are typically identified by use of words like “may”, “could”, “might”, “expect”, “anticipate”, “believe”, or similar words. Actual events or results may differ materially from the Company’s expectations, which are subject to a number of known and unknown risks and uncertainties including but not limited to changing market conditions, future actions by the United States Food and Drug Administration or equivalent foreign regulatory authorities. Other risk factors discussed in the Company’s financial reports may also affect the actual results achieved by the Company.
Contact:
Investor Relations: North Arm Capital Services, Linda Hughes, 1-877-945-1621, ([email protected])
